Denali Therapeutics Inc.
DNLIReported to SECin USCIK 0001714899Filings at SEC EDGAR
No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.
This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 6. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.
The most recent filings
Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.
| Filed by | Type | Value | Reported | Filed by | Value | Type | Shares | Reported |
|---|---|---|---|---|---|---|---|---|
| Chin Peter ScottChief Medical Officer | Open-market sell | $36,8681,654 shares | Sep 9, 2026 | Chin Peter ScottChief Medical Officer | $36,868 | Open-market sell | 1,654 | Sep 9, 2026 |
| Thornberry Nancy— | Open-market sell | $14,600615 shares | Sep 4, 2026 | Thornberry Nancy | $14,600 | Open-market sell | 615 | Sep 4, 2026 |
| Thornberry Nancy— | Open-market sell | $247,32810,824 shares | Sep 4, 2026 | Thornberry Nancy | $247,328 | Open-market sell | 10,824 | Sep 4, 2026 |
| Schuth Alexander O.COFO and Secretary | Open-market sell | $64,8822,768 shares | Sep 3, 2026 | Schuth Alexander O.COFO and Secretary | $64,882 | Open-market sell | 2,768 | Sep 3, 2026 |
| Watts Ryan J.President and CEO | Gift | nothing paid32,220 shares | Aug 14, 2026 | Watts Ryan J.President and CEO | nothing paid | Gift | 32,220 | Aug 14, 2026 |
Lobbying
From the quarterly LD-2 filings at the U.S. Senate — a different register, and a different kind of fact.
This is not a trade and it is not scored. A lobbying filing says who lobbied for whom, on which issues, and for how much — it says nothing about the share price and nothing about this company’s insiders. The link between the client names in that register and Denali Therapeutics Inc. is a reviewed rule of ours: an LD-2 names a client and carries no ticker, no CIK and no LEI.
Lobbying reported per quarter
reported amounts per quarter, latest version of each report
Reported income: what lobbying firms reported receiving from this company's clients, per quarter.